12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ALN-AT3 regulatory update

Alnylam said FDA granted Orphan Drug designation for ALN-AT3 to treat hemophilia B. The subcutaneous RNAi therapeutic...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >